- Home
- EMPD vs CRBP Comparison
EMPD vs CRBP Comparison
Compare EMPD & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMPD | CRBP |
|---|---|---|
| Founded | 2020 | 2009 |
| Country | United States | United States |
| Employees | 15 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.8M | 147.4M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | EMPD | CRBP |
|---|---|---|
| Price | $5.27 | $10.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.60 |
| AVG Volume (30 Days) | ★ 823.3K | 227.5K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | $23.49 | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $3.19 | $6.10 |
| 52 Week High | $11.37 | $20.56 |
Technical Indicators
Market Signals| Indicator | EMPD | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 67.12 | 59.58 |
| Support Level | $4.57 | $7.91 |
| Resistance Level | $5.59 | $10.62 |
| Average True Range (ATR) | 0.26 | 0.66 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 91.52 | 63.67 |
Price Performance
Historical ComparisonAbout EMPD Empery Digital Inc.
Empery Digital Inc is an all-electric, off-road powersports vehicle company developing and building electric two and four-wheel motorcycles and utility terrain vehicles, also known as side-by-sides, along with a complete line of upgrades and accessories. The company's products include motorcycle and UTV products that are all-electric and designed for off-road use.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.